IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.

Amit AkirovYona GreenmanBenjamin GlaserIrena S'chigolYossi MansiterskiYoav EizenbergIlana Shraga-SlutzkyIlan Shimon

Published in: Pituitary (2018)

IGF-1 levels may increase to clinically significant levels during cabergoline treatment for PRL-adenoma. We suggest IGF-1 monitoring in all patients treated with dopamine agonists and not only in those presenting symptoms of acromegaly.

Keyphrases

binding protein
growth hormone
uric acid
metabolic syndrome
combination therapy
case report
signaling pathway
replacement therapy